Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | TYK2 | P29597 | 3/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18593193 | 0.86 | JAK2 (0.38) | JAK2TYK2 | |
| SCHEMBL18592922 | 0.83 | JAK2 (0.37) | JAK2TYK2LRRK2 | |
| SCHEMBL18593175 | 0.82 | JAK2 (0.38) | JAK2TYK2LRRK2 | |
| SCHEMBL18592869 | 0.74 | KHK (0.41) | JAK2TYK2LRRK2 | |
| SCHEMBL18592873 | 0.74 | KHK (0.41) | JAK2TYK2LRRK2 | |
| SCHEMBL18592872 | 0.74 | KHK (0.41) | JAK2TYK2LRRK2 | |
| SCHEMBL23008368 | 0.73 | MAP4K4 (0.45) | LRRK2 | |
| SCHEMBL18593206 | 0.72 | JAK2 (0.37) | JAK2TYK2 | |
| SCHEMBL20380485 | 0.71 | LRRK2 (0.39) | JAK2TYK2LRRK2 | |
| SCHEMBL18592814 | 0.71 | LRRK2 (0.39) | JAK2TYK2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4327809-A2 | TYK2 INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-3344624-B1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20210047319-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-18 | — | — | US | disclosed |
| US-10781204-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-10023571-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023571-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170066763-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20170066763-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| WO-2017040757-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066763-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | JAK2 2/4885TYK2 1/4885LRRK2 269/4885 |
| US-10023571-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK1, JAK2 | JAK2 3/4885TYK2 1/4885LRRK2 259/4885 |
| US-20210047319-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | JAK2 2/4885TYK2 1/4885LRRK2 269/4885 |
| US-10781204-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK1, JAK2 | JAK2 3/4885TYK2 1/4885LRRK2 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.